Results 41 to 50 of about 31,287 (242)

Pneumocystis pneumonia occurrence and prophylaxis duration in kidney transplant recipients according to perioperative treatment with rituximab

BMC Nephrology, 2020
Background Pneumocystis pneumonia (PCP) is a life-threatening fungal infection that can occur in kidney transplantation (KT) recipients. A growing number of KT recipients are receiving perioperative treatment with rituximab, which is associated with ...
Young Hoon Kim, Jee Yeon Kim, Dong Hyun Kim, Youngmin Ko, Ji Yoon Choi, Sung Shin, Joo Hee Jung, Su-Kil Park, Sung-Han Kim, Hyunwook Kwon, Duck Jong Han   +10 more
doaj   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

PRIORITY Study: Baseline and Post-Rituximab Immune Profiles in a Pediatric Cohort

Journal of Human Immunity
BackgroundPediatric utilization of rituximab encompasses autoimmune, renal, hematologic, and neurologic conditions. Its association with secondary hypogammaglobulinemia and unmasking of inborn errors of immunity is well recognized.
Dr. Jenny Garkaby, Dr. Andrew Wong-Pack, Dr. Leena Ahmed, Dr. Tania Cellucci, Dr. Dua Meghna, Dr. Rahul Chanchlani, Zaina Khan, Zaeem Nadeem   +7 more
doaj   +1 more source

Increasing Operational Capacity and Reducing Costs of Rituximab Administration: A Costing Analysis

ACR Open Rheumatology, 2020
Objective Originator intravenous rituximab is an important rheumatology treatment but is costly, and administration requires several hours. Because biosimilar rituximab may cost less and subcutaneous rituximab requires a shorter visit, both may reduce ...
Zachary S. Wallace, Tyler Harkness, Kimberly G. Blumenthal, Hyon K. Choi, John H. Stone, Rochelle P. Walensky   +5 more
doaj   +1 more source

No tumor uptake on ⁸⁹Zr-rituximab-PET, concordant with CD20 expression in biopsy.

, 2017
Axial images, from left to right attenuation corrected PET, low dose CT and fused PET/CT image of patient 1. a) 89Zr-rituximab-PET shows no tumor uptake concordant with a CD20-negative liver biopsy. b) Corresponding tumor location on 18F-FDG-PET.
Guus A. M. S. van Dongen (506975), Daphne de Jong (3622187), Danielle J. Vugts (506973), Otto S. Hoekstra (300973), Yvonne W. S. Jauw (3622184), Josée M. Zijlstra (3622181), Sonja Zweegman (482354), Marc C. Huisman (3622178)   +7 more
core   +1 more source

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket, J. Lycke, J. Salzer, F. Piehl, K. Fink, N. Lange, J. Mellergård, C. Malmeström, P. Sundström, I. Erngren, A. al‐Grety, E. Freyhult, K. Kultima, J. Burman, A. Svenningsson   +14 more
wiley   +1 more source

Risk Factors for Persistent Hypogammaglobulinemia in Pediatric and Young Adult Patients Receiving Rituximab

Journal of Human Immunity
RationaleRituximab is an anti-CD20 monoclonal antibody that can cause persistent hypogammaglobulinemia (PH) in 20–45% of patients, depending on the patient population. Risk factors for PH in pediatric patients following rituximab have been inconsistently
Kevin Ackerman, Nathaniel Srikureja, Jennifer Heimall, Di Sun   +3 more
doaj   +1 more source

Effects of rituximab dose on hepatitis B reactivation in patients with resolved infection undergoing immunologic incompatible kidney transplantation

Scientific Reports, 2018
Sensitized patients received desensitization therapy with rituximab for kidney transplantation. However, the impact of rituximab dose on hepatitis B virus (HBV) reactivation is unknown.
Juhan Lee, Jun Yong Park, Deok Gie Kim, Jee Youn Lee, Beom Seok Kim, Myoung Soo Kim, Soon Il Kim, Yu Seun Kim, Kyu Ha Huh   +8 more
doaj   +1 more source

Applying Rituximab During the Conditioning Regimen Prevents Epstein–Barr Virus Infection Following Allogeneic Hematopoietic Stem Cell Transplant in a Children’s Cohort: A Retrospective Case–Control Study

Infectious Diseases and Therapy, 2023
Introduction Since hematopoietic stem cell transplant (HSCT) is an important therapy for malignant and non-malignant pediatric diseases, improving transplant-related mortality remains a challenge. Currently, rituximab, a monoclonal antibody of anti-CD20,
Yongsheng Ruan, Libai Chen, Tingting Luo, Danfeng Xie, Wei Cao, Xuan Liu, Qiujun Liu, Yuhua Xiao, Cuiling Wu, Jianyun Wen, Juan Li, Jiangnan Meng, Xuedong Wu, Xiaoqin Feng   +13 more
doaj   +1 more source

Leucemia Linfoblástica aguda recidivada tratada com rituximab: relato de caso e revisão de literatura. [PDF]

, 2007
Trabalho de Conclusão de Curso - Universidade Federal de Santa Catarina. Curso de Medicina.
Borbinhão, Rodrigo Widholzer
core